Lonidamine plus Epirubicin and Cyclophosphamide in Advanced Breast Cancer. A Phase II Study

Author： Gardin G.   Barone C.   Nascimben O.   Ianniello G.   Sturba F.   Contu A.   Pronzato P.   Rosso R.  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.32, Iss.1, 1996-01, pp. : 176-177

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer

By Esteban E.  

Breast Cancer Research and Treatment, Vol. 62, Iss. 2, 2000-07 ,pp. : 127-133

Springer Publishing Company

Access to resources Recommend Favorite

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*

By Conte P.F.  

Breast Cancer Research and Treatment, Vol. 68, Iss. 2, 2001-07 ,pp. : 171-179

Springer Publishing Company

Access to resources Recommend Favorite

A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)

By Aogi Kenjiro   Saeki Toshiaki   Nakamura Seigo   Kashiwaba Masahiro   Sato Nobuaki   Masuda Norikazu   Rai Yoshiaki   Ohno Shinji   Kuroi Katsumasa   Nishimura Reiki   Miyakoda Keiko   Akiyama Futoshi   Kurosumi Masafumi   Ikeda Tadashi  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 598-606

Springer Publishing Company

Access to resources Recommend Favorite

Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study

By De Lena M.   Lorusso V.   Latorre A.   Fanizza G.   Gargano G.   Caporusso L.   Guida M.   Catino A.   Crucitta E.   Sambiasi D.   Mazzei A.  

European Journal of Cancer, Vol. 37, Iss. 3, 2001-02 ,pp. : 364-368

Elsevier

Access to resources Recommend Favorite

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

By Morales Serafín   Lorenzo Antonio   Ramos Manuel   Ballesteros Pedro   Méndez Miguel   Almanza Concepción   Castellanos Javier   Moreno-Nogueira José   Casal Joaquín   Lizón José   Oltra Amparo   Frau Adolfo   Machengs Ignacio   Galán Antonio   Belón Joaquín   Llorca Cristina  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 1, 2004-01 ,pp. : 75-81

Springer Publishing Company

Access to resources Recommend Favorite